Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have marginal zone lymphoma or a low-grade B-cell lymphoma that has come back or not responded to previous treatment.
- You need to have had at least one prior treatment that included a CD20 antibody (like rituximab).
- You must have stage 2, 3, or 4 lymphoma that requires treatment.
- You must be 18 years or older and have adequate organ function (kidneys, liver, bone marrow).
- You should not have certain heart conditions, active infections, or other recent cancers.
- You must be able to swallow pills and not have any condition that would interfere with absorption of oral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies mosunetuzumab alone or combined with zanubrutinib to treat people with follicular lymphoma that is advanced or causing problems. It’s meant to see which approach works better and is safe for long-term treatment.
This trial tests a combination of two targeted drugs, mosunetuzumab and zanubrutinib, for people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
This study tests three different treatment combinations using new drugs (mosunetuzumab alone, or combined with zanubrutinib or polatuzumab vedotin) for marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to find which combination works best and is safest.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.